Depression and Anxiety in Parkinson’s Disease

This review presents data from recent studies throughout the world on anxious-depressive disorders in patients with Parkinson’s disease (PD); their features and epidemiology are presented, along with details of pathogenesis, clinical properties, and contemporary diagnostic and therapeutic methods. D...

Full description

Saved in:
Bibliographic Details
Published in:Neuroscience and behavioral physiology 2018-06, Vol.48 (5), p.636-640
Main Authors: Akhmadeeva, G. N., Magzhanov, R. V., Tayupova, G. N., Baitimerov, A. R., Khidiyatova, I. M.
Format: Article
Language:English
Subjects:
Antidepressants
Anxiety
Behavioral Sciences
Biomedical and Life Sciences
Biomedicine
Desipramine
Epidemiology
Mental depression
Movement disorders
Neurobiology
Neurodegenerative diseases
Neurosciences
Parkinson's disease
Patients
Pramipexole
Tricyclic antidepressants
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:This review presents data from recent studies throughout the world on anxious-depressive disorders in patients with Parkinson’s disease (PD); their features and epidemiology are presented, along with details of pathogenesis, clinical properties, and contemporary diagnostic and therapeutic methods. Depression is encountered in an average of 40–50% of patients with PD and anxiety in 17–43%. Only one medication –pramipexole (a dopamine receptor agonist) – is recommended for the treatment of depression. Two more, nortriptyline and desipramine, which are tricyclic antidepressants, are “probably” effective. There are as yet no clear recommendations for the treatment of anxiety. Overall, methods for the treatment of anxious/depressive disorder in PD have received insufficient study, suggesting the need for future large-scale studies.
ISSN:0097-0549
1573-899X
DOI:10.1007/s11055-018-0609-1